Skip to main content
Helen Lawler, MD, Endocrinology, Aurora, CO

Helen Margaret Lawler MD

Diabetes, Lipid Metabolism


Physician

Join to View Full Profile
  • 12605 E 16th Ave# F402Aurora, CO 80045

  • Phone+1 720-848-0000

  • Fax+1 720-848-2653

Dr. Lawler is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Endocrinology, Diabetes, and Metabolism, 2010 - 2013
  • University of Colorado
    University of ColoradoResidency, Internal Medicine, 2007 - 2010
  • Virginia Commonwealth University School of Medicine
    Virginia Commonwealth University School of MedicineClass of 2007

Certifications & Licensure

  • CO State Medical License
    CO State Medical License 2010 - 2027
  • Internal Medicine
    American Board of Internal Medicine Internal Medicine
  • Endocrinology, Diabetes and Metabolism
    American Board of Internal Medicine Endocrinology, Diabetes and Metabolism

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2013

Clinical Trials

Publications & Presentations

PubMed

Lectures

  • Managing the Post-Bariatric Patient: Hypoglycemia, Changes in Beta-Cell Function, and Beyond 
    ENDO 2019 - New Orleans, LA - 3/23/2019
  • Managing the Post-Bariatric Patient: Hypoglycemia, Changes in Beta-Cell Function, and Beyond (Repeat) 
    ENDO 2019 - New Orleans, LA - 3/23/2019

Press Mentions

  • Xeris Pharmaceuticals Announces Positive Findings from the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric Surgery
    Xeris Pharmaceuticals Announces Positive Findings from the Outpatient Portion of a Phase 2 Proof-of-Concept Study of Its Developmental Ready-to-Use (RTU) Glucagon in Patients at Risk of Postprandial Hypoglycemia Following Bariatric SurgeryMay 22nd, 2020

Professional Memberships

Viewing the full profile is available to verified healthcare professionals only.

Find your profile and take control of your online presence: